Interleukin 12: still a promising candidate for tumor immunotherapy?
Open accessThe DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Abstract
Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous attempts to develop IL-12-based therapies for human use had severely toxic consequences (Lasek et al., 2014) likely due to systemic administration routes.”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Lasek et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5 retracted
(1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1575 · Cited by 152 · cited 1×
“[85], and TNF-mediated apoptosis of fibroblasts [86].”
RetractedThe IL-15Rα Chain Signals Through Association with Syk in Human B Cells
Bulanova, E., Budagian, V., Pohl, T., Krause, H., Dürkop, H., Paus, R., & Bulfone-Paus, S. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6292 · Cited by 84 · cited 2×
“and dendritic cells in particular, simultaneously express the IL15Ra chain, which, in contrast to IL-2Ra, binds IL-15 with high affinity (Ka 10 11 M) [43] and can mediate signal transduction [44].”
BackgroundRetractedA promiscuous liaison between IL‐15 receptor and Axl receptor tyrosine kinase in cell death control
Budagian, V., Bulanova, E., Orinska, Z., Thon, L., Mamat, U., Bellosta, P., Basilico, C., Adam, D., Paus, R., & Bulfone‐Paus, S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600874 · Cited by 75 · cited 2×
“On the other hand, both the IL-2/15b chain and a unique IL-15Ra chain signal through SYK protein tyrosine kinase of the SYK/ZAP-70 family [44,69], and IL-15Ra activates protein tyrosine kinase AXL [70].”
BackgroundRetractedBulanova, E., Budagian, V., Duitman, E., Orinska, Z., Krause, H., Rückert, R., Reiling, N., & Bulfone-Paus, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610036200 · Cited by 63 · cited 2×
“On the other hand, some soluble IL-15Ra isoforms released as a result of alternative splicing or proteolytic cleavage [57] could inhibit the activity of IL-15 [57,58], and tumor cells can release proteolytically cleaved IL-15Ra as one of their tumor evasion strategies [59].”
BackgroundRetractedReverse Signaling through Membrane-bound Interleukin-15
Budagian, V., Bulanova, E., Orinska, Z., Pohl, T., Borden, E. C., Silverman, R. H., & Bulfone‐Paus, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403182200 · Cited by 60
RetractedChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In contrast to mice, human tumors seem to consist of much more heterogenous population of tumor cells, developed as a result of tumor escape mechanisms, and contain strongly immunosuppressive soluble and cellular components (including myeloid-derived suppressor cells) that are resistant to IL-12-induced antitumor acti…”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-modified T cells specific for CD19 have recently shown promise in the treatment for acute leukemia and chronic lymphocytic leukemia [185, 186].”
BackgroundDevelopment of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134 · cited 1×
“The main source of IL-12 in humans is the activated antigen-presenting cells, such as dendritic cells [4], especially of the CD1c+ phenotype [5], as well as the hematopoietic phagocytes (monocytes, macrophages, and also neutrophils) [6], but IL-12 can also be produced by other cell types [7, 8].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Cited by
Items 101–200 of 550
The HDAC2-SP1 Axis Orchestrates Protumor Macrophage Polarization
Zheng, X., Sarode, P., Weigert, A., Turkowski, K., Chelladurai, P., Günther, S., Kuenne, C. T., Winter, H., Stenzinger, A., Reu, S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1270 · Cited by 59
Synthetic tumor networks for screening drug delivery systems
Prabhakarpandian, B., Shen, M.-C., Nichols, J. B., Garson, C. J., Mills, I. R., Matar, M. M., Fewell, J. G., & Pant, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.018 · Cited by 57
In situ genetic engineering of tumors for long-lasting and systemic immunotherapy
Tzeng, S. Y., Patel, K. K., Wilson, D. R., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916039117 · Cited by 57
Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
Moody, R., Wilson, K., Jaworowski, A., & Plebanski, M. (2020) · Cancers · doi:10.3390/cancers12030673 · Cited by 57
Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives
Zaggana, E., Konstantinou, M. P., Krasagakis, G. H., de Bree, E., Kalpakis, K., Mavroudis, D., & Krasagakis, K. (2022) · Cancers · doi:10.3390/cancers15010103 · Cited by 56
Polymeric nanoparticle gel for intracellular mRNA delivery and immunological reprogramming of tumors
Neshat, S. Y., Chan, C. H. R., Harris, J. J., Zmily, O. M., Est-Witte, S. E., Karlsson, J. E., Shannon, S. R., Jain, M., Doloff, J. C., Green, J. J., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122185 · Cited by 56
Immunoengineering with biomaterials for enhanced cancer immunotherapy
Xie, Y., Wei, L., & Tang, L. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1506 · Cited by 55
Radiotherapy in Combination With Cytokine Treatment
Palata, O., Podzimkova, N., Nedvedova, E., Umprecht, A., Sadilkova, L. K., Jelinkova, L. P., Špíšek, R., & Adkins, I. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00367 · Cited by 55
Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23
Kansara, M., Thomson, K., Pang, P., Dutour, A., Mirabello, L. J., Acher, F., Pin, J., Demicco, E. G., Yan, J., Teng, M. W. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0154 · Cited by 55
Martinović, K. M., Babović, N. L., Džodić, R. R., Jurišić, V., Matković, S., & Konjević, G. M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0479-z · Cited by 54
“On the other hand, considering that their therapeutic effects are limited, many other cytokines, such as IL-12 and IL-18 have been investigated in this disease [14,15].”
BackgroundKwon, H.-J., Kim, N., & Kim, H. S. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.42 · Cited by 54
Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
Bai, R., & Cui, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890166 · Cited by 52
EMT-induced immune evasion: connecting the dots from mechanisms to therapy
Imodoye, S. O., & Adedokun, K. A. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01229-4 · Cited by 52
“While overexpression of MICA/B predicts improved clinical outcome [42], KIR overexpression correlates with poor prognosis in NSCLC [43], suggesting that NK cells are critical for immune surveillance against tumor progression in NSCLC. Recently, an important finding was published elucidating the…”
Fantini, M. C., Arlen, P. M., & Tsang, K. Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275904 · Cited by 52
“Although IL-12 has demonstrated promising ef fi cacy in animal models against both solid tumors and hematologic malignancies, clinical trials did not yield convincing results (64).”
BackgroundResultSingle Injection of IL-12 Coacervate as an Effective Therapy Against B16-F10 Melanoma in Mice
Hwang, M., Fecek, R. J., Qin, T., Storkus, W., & Wang, Y. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.035 · Cited by 44
Samimi, M. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00427-9 · Cited by 51
Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
Bhatnagar, S., Revuri, V., Shah, M., Larson, P. G., Shao, Z., Yu, D., Prabha, S., Griffith, T. S., Ferguson, D. M., & Panyam, J. (2022) · Cancers · doi:10.3390/cancers14246091 · Cited by 49
“It was interesting to note that the combination treatment resulted in substantially elevated levels of IL-12, a key cytokine that orchestrates the Th1 anticancer immune response [41].”
Cancer Immunotherapy and Delivery System: An Update
Yang, M. J., Olaoba, O. T., Zhang, C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081630 · Cited by 49
Mpendo, J., Mutua, G. N., Nyombayire, J. M., Ingabire, R., Nanvubya, A., Anzala, O. A., Karita, E., Hayes, P., Kopycinski, J. T., Dally, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134287 · Cited by 48
Marofi, F., Rahman, H. S., Thangavelu, L. P., Dorofeev, A. E., Bayas-Morejón, F., Shirafkan, N., Shomali, N., Chartrand, M. S., Jarahian, M., Vahedi, G., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02251-7 · Cited by 48
“However, there are still serious toxicity concerns about the clinical application of IL-12 due to its pleiotropic nature [196].”
BackgroundJafarzadeh, A., Minaee, K., Farsinejad, A., Nemati, M., Khosravimashizi, A., Daneshvar, H., Mohammadi, M. M., Sheikhi, A., & Ghaderi, A. A. (2015) · PubMed · Cited by 48
Salazar, M. L., Jiménez, J. M., Villar, J., Rivera, M., Báez, M., Manubens, A., & Becker, M. I. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009525 · Cited by 47
“As demonstrated previously, N-deglycosylated hemocyanins have remnant mannoses and fucoses; the latter are also capable of binding to innate immune receptors, inducing alternative Nf- B activation pathways (60).”
BackgroundMohme, M., Maire, C. L., Geumann, U., Schliffke, S., Dührsen, L., Fita, K. D., Akyüz, N., Binder, M., Westphal, M., Guenther, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0803 · Cited by 47
“One of its main effector molecules is IFNg and it induces polarization of CD4þ T cells to the TH1 type (20).”
BackgroundLugani, S., Halabi, E. A., Oh, J., Köhler, R. H., Peterson, H. M., Breakefield, X. O., Chiocca, E. A., Miller, M. A., Garris, C., & Weissleder, R. (2022) · Advanced Materials · doi:10.1002/adma.202208782 · Cited by 46
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
Jahan, N., Ghouse, S. M., Martuza, R. L., & Rabkin, S. D. (2021) · Viruses · doi:10.3390/v13091740 · Cited by 46
Intratumoral immunotherapy relies on B and T cell collaboration
Sagiv-Barfi, I., Czerwinski, D. K., Shree, T., Lohmeyer, J. J. K., & Levy, R. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn5859 · Cited by 46
Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer
Wang, L., Zhu, B., Zhang, M., & Wang, X. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.008 · Cited by 45
Mohammed, S. I., Torres-Luquis, O. J., Walls, E. K., & Lloyd, F. P. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12494 · Cited by 45
Ren, G., Tian, G., Liu, Y., He, J., Gao, X., Yu, Y.-H., Liu, X., Zhang, X., Sun, T., Liu, S., et al. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615601521 · Cited by 44
Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer
Cheng, C.-T., Castro, G., Liu, C., & Lau, P. Y. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.01.027 · Cited by 44
Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1
Kim, K.-J., Moon, D., Kong, S. J., Lee, Y. S., Yoo, Y., Kim, S. Y., Kim, C., Chon, H. J., Kim, J.-H., & Choi, K. (2020) · Gene Therapy · doi:10.1038/s41434-020-00205-x · Cited by 44
HBx-induced miR-21 suppresses cell apoptosis in hepatocellular carcinoma by targeting interleukin-12
Yin, D., Wang, Y., Sai, W., Zhang, L., Miao, Y., Cao, L., Zhai, X., Feng, X., & Yang, L. (2016) · Oncology Reports · doi:10.3892/or.2016.5026 · Cited by 43
“In addition, several other mechanisms of IL-12 strongly contribute to antitumor activities (20,21), and the antitumor activity of IL-12 can be improved by its combination with various therapeutics (22,23).”
BackgroundPishavar, E., Oroojalian, F., Ramezani, M., & Hashemi, M. (2019) · Biotechnology Progress · doi:10.1002/btpr.2952 · Cited by 43
Espinoza‐Sánchez, N. A., Chimal-Ramírez, G. K., Mantilla, A., & Fuentes‐Pananá, E. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00205 · Cited by 43
Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Wang, H., Borlongan, M. C., Kaufman, H. L., Le, U. M., Nauwynck, H., Rabkin, S. D., & Saha, D. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008025 · Cited by 42
“37 As such, many IL-12 expressing oHSVs have been developed as anticancer agents, which we have presented below.”
BackgroundIL-12 immunotherapy of Braf-induced papillary thyroid cancer in a mouse model
Parhar, R. S., Zou, M., Al-Mohanna, F. A., Baitei, E. Y., Assiri, A. M., Meyer, B. F., & Shi, Y. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.126 · Cited by 43
Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy
Yang, X., Fan, J., Wu, Y., Ma, Z., Huang, J., Zhang, Y., Zhou, Z. M., Mo, F., Liu, X., Yuan, H., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102443 · Cited by 42
Xu, L., Yao, L.-J., Jiang, D., Zhou, L., Chen, M., Liao, W.-Z., Zou, W., & Peng, H. (2021) · Parasites & Vectors · doi:10.1186/s13071-021-05032-6 · Cited by 42
“Additionally, in tumor immunotherapy, IL-12 therapy induces Th1 cell differentiation [62], increases the infiltration of NK and CD8+ T cells to tumor sites [63] and triggers an anti-angiogenic program to exert anti-tumor activity [64, 65].”
BackgroundNatural killer cell-mediated immune surveillance in cancer: Role of tumor microenvironment
Saadh, M. J., Rasulova, I., Khalil, M. N. A., Farahim, F., Sârbu, I., Ciongradi, C. I., Omar, T. M., Alhili, A., Jawad, M. J., Hani, T., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155120 · Cited by 41
Advances in the mechanisms of action of cancer-targeting oncolytic viruses (Review)
Lin, C., Xiang, G., Zhu, X., Xiu, L., Sun, J., & Zhang, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.7829 · Cited by 40
“These responses were associated with intra-tumoral IL‑12 mRNA expression, reflected as a decrease in the size of the injected and distant lesions (55).”
BackgroundJi, Y. C., Liu, X., Huang, M. T.-H., Jiang, J., Liao, Y., Liu, Q., Chang, C. H., Liao, H., Lu, J., Wang, X., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.027 · Cited by 40
“IL-12 targets natural killer (NK) cells and T lymphocytes, effectively stimulating the secretion of IFN-γ (a cytokine coordinating anticancer defense) [35].”
BackgroundInterleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer
Cohen, C. A., Shea, A. A., Heffron, C. L., Schmelz, E. M., & Roberts, P. C. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0049 · Cited by 40
Ongaro, T., Matasci, M., Cazzamalli, S., Gouyou, B., Luca, R. D., Neri, D., & Villa, A. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.12.004 · Cited by 40
Role of Adenoviruses in Cancer Therapy
Tseha, S. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.772659 · Cited by 40
“However, findings from clinical trials indicated severe side effects of systemic administration of IL-12 that markedly dampened hopes of the successful use of this cytokine in cancer patients (138).”
BackgroundChen, P., Yang, W., Nagaoka, K., Huang, G. L., Miyazaki, T., Hong, T., Li, S., Igarashi, K., Takeda, K., Kakimi, K., et al. (2023) · Advanced Science · doi:10.1002/advs.202205139 · Cited by 39
Gene Therapy Approaches Against Cancer Using in Vivo and ex Vivo Gene Transfer of Interleukin-12
Hernández-Alcoceba, R., Poutou, J., Ballesteros-Briones, M. C., & Smerdou, C. (2016) · Immunotherapy · doi:10.2217/imt.15.109 · Cited by 39
Strauss, J., Deville, J., Sznol, M., Ravaud, A., Maruzzo, M., Pachynski, R. K., Gourdin, T. S., Maio, M., Dirix, L. Y., Schlom, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005813 · Cited by 38
Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy
Wang, H., Borlongan, M. C., Hemminki, A., Basnet, S., Sah, N., Kaufman, H. L., Rabkin, S. D., & Saha, D. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.099 · Cited by 38
“50 It produces multifaceted antitumor immune effects: (1) stimulates T cells (both CD4 + and CD8 + T cells) and NK cells to produce immune effectors such as TNF-a and IFN-c ; (2) induces differentiation of naive T cells toward a Th1 phenotype; and (3) inhibits tumor angiogenesis through the IFN-c -…”
Kamenšek, U., Čemažar, M., Tratar, U. L., Uršič, K., & Serša, G. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2133-0 · Cited by 39
Gasparri, A. M., Sacchi, A., Basso, V., Cortesi, F., Freschi, M., Rrapaj, E., Bellone, M., Casorati, G., Dellabona, P., Mondino, A., et al. (2019) · Small · doi:10.1002/smll.201903462 · Cited by 37
Sheikhsaran, F., Sadeghpour, H., Khalvati, B., Entezar-Almahdi, E., & Dehshahri, A. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.11.008 · Cited by 37
Next Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 37
“Il-12 also increases INF-γ production from NKs and T cells which in turn leads to increased antigen presentation through upregulation of MHC molecules [47].”
BackgroundHarnessing molecular recognition for localized drug delivery
Liu, R., Zuo, R., & Hudalla, G. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.008 · Cited by 37
“In particular, they fused lumican to mouse serum albumin (MSA) and a cytokine (IL-2 or IL-12), where MSA served as a linker to ensure access of receptors to cytokines when bound to collagen, as well as to increase the molecular weight and thereby reduce diffusive flux away from the tumor.”
BackgroundInfluentialSubsite heterogeneity in the profiles of circulating cytokines in colorectal cancer
Krzystek‐Korpacka, M., Zawadzki, M., Kapturkiewicz, B., Lewandowska, P., Bednarz‐Misa, I., Górska, S., Witkiewicz, W., & Gamian, A. (2018) · Cytokine · doi:10.1016/j.cyto.2018.05.015 · Cited by 36
The multifaceted role of IL-12 in cancer
Habiba, U., Rafiq, M., Khawar, M. B., Nazir, B., Haider, G., & Nazir, N. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100053 · Cited by 36
Th1-Biased Immunomodulation and In Vivo Antitumor Effect of a Novel Piperine Analogue
Santos, J. A. F., Brito, M. T., Ferreira, R. C., Moura, A. P. G., de Sousa, T. K. G., Batista, T. M., Mangueira, V. M., Leite, F. C., da Cruz, R. M. D., Vieira, G. C., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092594 · Cited by 36
“Furthermore, IL-12 is a cytokine that orchestrates the Th1 type immune response, cytotoxic [41].”
BackgroundIL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
Pires, I. S., Covarrubias, G., Gomerdinger, V. F., Backlund, C. M., Bueno, E. N., Billingsley, M. M., Pryor, M. L., Shanker, A., Gordon, E., Wu, S., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02390-9 · Cited by 35
Advances in Anticancer Protein Delivery using Micro‐/Nanoparticles
Sun, W., Lü, Y., & Gu, Z. (2014) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.201400140 · Cited by 35
Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+T cells
Jung, K., Ha, J.-H., Kim, J., Kim, J.-A., Kim, Y., Kim, Y., & Kim, Y. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438800 · Cited by 35
“In previous mouse studies, repeated daily injection of rmIL12 (1–5 mg) exerted significant antitumor activity.30,31 Mono-mIL12-Fc more efficiently eliminates large established tumors than bi-mIL12-Fc To further evaluate the antitumor activity of mIL12-Fc proteins against large established tumors, Balb/c mice bearing C…”
BackgroundInfluentialPiscatelli, J. A., Ban, J., Lucas, A. T., & Zamboni, W. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010114 · Cited by 36
Role of interleukin-12 gene polymorphisms in the onset risk of cancer: a meta-analysis
Zheng, Y. F., Wang, M., Tian, T., Liu, K., Liu, X., Zhai, Y., Lin, S., Yang, P., Li, S., Dai, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16080 · Cited by 35
“Interleukin-12 (IL-12), which is characteristic as a link between the innate and acquired immune response [7], is one of the most potential candidates for tumor immunotherapy.”
BackgroundParking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
Evgin, L., & Vile, R. G. (2021) · Cancers · doi:10.3390/cancers13051106 · Cited by 34
“Encoding the checkpoint blockade molecule and IL12 in the virus is a particularly attractive strategy to produce locally high concentrations at bioactive sites, where systemic delivery is associated with adverse events [99].”
BackgroundWang, Z., Chen, Y., Wu, H., Wang, M., Mao, L., Guo, X., Zhu, J., Ye, Z., Luo, X., Yang, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57997-w · Cited by 33
“Firstly, IL-12 can activate T cells and NK cells to drive Th1 differentiation of CD4 + T cells via enhanced production of IFN-γ and augments the cytolytic ability of NK and CD8 + T cells towards tumor cells via granzyme B and perforin secretion 1 .”
BackgroundTratar, U. L., Milevoj, N., Čemažar, M., Žnidar, K., Uršič, K., Brožič, A., Tomsič, K., Serša, G., & Tozon, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110274 · Cited by 34
Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities
Chowdhary, S., Deka, R., Panda, K., Kumar, R., Solomon, A. D., Das, J., Kanoujiya, S. N., Gupta, A. K., Sinha, S., Ruokolainen, J., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01080 · Cited by 34
Bagchi, S., Li, S., & Wang, C.-R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1213932 · Cited by 33
“Interestingly, both CpG and IL-12 have been used in pre-clinical studies as anticancer therapy.(38,46) Both these immunostimu-”
BackgroundBeyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
Eckert, F., Gaipl, U. S., Niedermann, G., Hettich, M., Schilbach, K., Huber, S. M., & Zips, D. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2016.12.006 · Cited by 33
“Systemic administration of IL-12 has already shown efficacy against solid tumours but induced dose-limiting toxicity [36,95].”
BackgroundDi, S., & Li, Z. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5025-6 · Cited by 31
“In a recent report, MyD88/CD40 was able to promote higher levels of IL2 production in CAR-T cells than CD28 (Lasek et al., 2014).”
Feeney, O. M., Gracia, G., Brundel, D. H. S., Trevaskis, N. L., Cao, E., Kaminskas, L. M., & Porter, C. J. H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.002 · Cited by 31
Clinical Applications and Immunological Aspects of Electroporation-Based Therapies
da Luz, J. C. D. S., Antunes, F., Clavijo-Salomon, M. A., Signori, E., Tessarollo, N. G., & Strauss, B. E. (2021) · Vaccines · doi:10.3390/vaccines9070727 · Cited by 30
Tiwari, P., Shukla, R. P., Yadav, K., Panwar, D., Agarwal, N., Kumar, A., Singh, N., Bakshi, A. K., Marwaha, D., Gautam, S., et al. (2024) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2024.108702 · Cited by 30
Hu, M., Zhou, X., Wang, Y., Guan, K., & Huang, L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.053 · Cited by 29
The chemical biology of IL-12 production via the non-canonical NFkB pathway
Koch, P. D., Pittet, M. J., & Weissleder, R. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00022a · Cited by 29
Prospects for NK Cell Therapy of Sarcoma
Lachota, M., Vincenti, M., Winiarska, M., Boye, K., Zagożdżon, R., & Malmberg, K. (2020) · Cancers · doi:10.3390/cancers12123719 · Cited by 29
“Unfortunately, systemic cytokine therapies are associated with severe side effects [181,182].”
BackgroundSelf-citationZheng, J., Wang, X., Yu, J., Zhan, Z., & Guo, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.997665 · Cited by 29
“Studies have found that the level of expression of related cytokines of patients whose tumor diameters are longer has increased significantly, but the influence of cytokines on tumor diameters needs further examination (27).”
BackgroundMehralizadeh, H., Nazari, A., Oruji, F., Roostaie, M., Hosseininozari, G., Yazdani, O., Esbati, R., & Roudini, K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154528 · Cited by 29
Haley, J. S., Hibler, E. A., Zhou, S., Schmitz, K. H., & Sturgeon, K. M. (2019) · Cancer · doi:10.1002/cncr.32530 · Cited by 29
“IL-12 is highly involved in the functional activity of natural killer cells and T lymphocytes, and for this reason this proinflammatory cytokine can have beneficial or detrimental effects.(37,38) IL-10 plays a major role in resolving the inflammatory response.”
BackgroundSignificance of 5-S-Cysteinyldopa as a Marker for Melanoma
Wakamatsu, K., Fukushima, S., Minagawa, A., Omodaka, T., Hida, T., Hatta, N., Takata, M., Uhara, H., Okuyama, R., & Ihn, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020432 · Cited by 29
Antibody fusions with immunomodulatory proteins for cancer therapy
Müller, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.001 · Cited by 29
Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer
Wang, W., Zhao, D., Zhou, Y., Hu, X., Sun, Z., Yu, G., Wu, W., Chen, S., Kuang, J.-L., Xu, G., et al. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.3 · Cited by 29
Kułach, N., Pilny, E., Cichoń, T., Czapla, J., Jarosz–Biej, M., Rusin, M., Drzyzga, A., Matuszczak, S., Szala, S., & Smolarczyk, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-97435-9 · Cited by 28
Zhang, H., Feng, Y., Xie, X., Song, T., Yang, G., Su, Q., Li, T., Li, S., Wu, C., You, F., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101375 · Cited by 28
Roquilly, A., David, G., Cinotti, R., Vourc’h, M., Morin, H., Rozec, B. R., Retière, C., & Asehnoune, K. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.08.006 · Cited by 28
Cutrera, J. J., King, G., Jones, P. D., Kicenuik, K., Gumpel, E., Xia, X., & Li, S. (2014) · Current Gene Therapy · doi:10.2174/1566523214666141127093654 · Cited by 28
Jafarzadeh, A., Ahangar-Parvin, R., Nemat, M., Taghipour, Z., Shamsizadeh, A., Ayoobi, F., & Hassan, Z. M. (2017) · PubMed Central · doi:10.22038/ajp.2016.7002 · Cited by 28
“IL-12 receptor is expressed on a number of immune cells, including NK cells, T and B lymphocytes (de Paus et al., 2013; Lasek et al., 2014).”
InfluentialAntitumor Activities of Interleukin-12 in Melanoma
Gao, W., Pan, J., & Pan, J. (2022) · Cancers · doi:10.3390/cancers14225592 · Cited by 27
“The detailed introduction of IL-12 irAE was seen in Lasek’s review [72].”
BackgroundRegué, D. R., Fabian, K. P., Watson, A. R., Fecek, R. J., Storkus, W. J., & Thomson, A. W. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1146841 · Cited by 27
TRAF3IP2, a novel therapeutic target in glioblastoma multiforme
Alt, E., Barabadi, Z., Pfnür, A., Ochoa, J. E., Daneshimehr, F., Lang, L. M., Lin, D., Braun, S. E., Chandrasekar, B., & Izadpanah, R. (2018) · Oncotarget · doi:10.18632/oncotarget.25710 · Cited by 27
“In fact, in a recently initiated clinical trial, IL-12 is being tested as an adjuvant in cancer vaccines and a tumor-targeting immunocytokine [40].”
BackgroundBattula, S. K., Papastoitsis, G., Kaufman, H. L., Wittrup, K. D., & Schmidt, M. M. (2023) · JCI Insight · doi:10.1172/jci.insight.168224 · Cited by 26
“Through a combination of direct signaling and indirect effects of IFN-γ upregulation, IL-12 can induce immune cell recruitment, costimulation, myeloid cell repolarization, and antigen presentation (5).”
BackgroundDNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies
Kazakova, A., Zhelnov, P., Sidorov, R. Y., Rogova, A. S., Vasileva, O., Ivanov, R. A., Reshetnikov, V. V., & Muslimov, A. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457327 · Cited by 27
“IL-12 stimulates the secretion of IFN-g by NK cells and by CD8 + and CD4 + T cells (80).”
BackgroundInterleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy
Alkayyal, A. A., Mahmoud, A. B., & Auer, R. C. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.04.002 · Cited by 26
Littwitz-Salomon, E., Dittmer, U., & Sutter, K. (2016) · Retrovirology · doi:10.1186/s12977-016-0311-8 · Cited by 26
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 29
Huang, C., Li, Z., Zhu, J., Chen, X., Hao, Y., Yang, R., Huang, R., Zhou, J., Wang, Z., Xiao, W., et al. (2021) · Aging · doi:10.18632/aging.202410 · Cited by 26
Fercher, C., Keshvari, S., McGuckin, M. A., & Barnard, R. T. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217748575 · Cited by 26
Xu, M., Yu, J., Zhang, C., Xu, C., Wei, X., & Pu, K. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202308362 · Cited by 25
Tasaki, M., YAMASHITA, M., Arai, Y., Nakamura, T., & Nakao, S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02947-y · Cited by 25
“IL-12, a broad spectrum immune activator [17], and IL-7, a key molecule for T cell homeostasis [18], may also impact the architecture of the intratumoral TCR repertoire, though it is completely unknown whether IL-7, IL-12 and their combination in an oncolytic vaccinia virus platform enhance TCR diversity or clonality.”
BackgroundSousa, F., Lee, H. C., de Almeida, M. S., Bazzoni, A., Rothen‐Rutishauser, B., & Petri‐Fink, A. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01509-2 · Cited by 24
“…because it stimulates interferon (IFN)-γ production by T and natural killer (NK) cells, decreases the angiogenesis, and changes the cancer microenvironment from one that contains T H 0 and M2-type phenotype macrophages to one richer in T H 1 cells and inflammatory M1-type macrophages [7, 8].”
BackgroundEngineered dendritic cells-derived extracellular vesicles for cancer immunotherapy
Coelho, M. O., Quintas, S. T., Sarmento, B. F. C. C., Wever, O. D., & Castro, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113620 · Cited by 24
Assessing the Role of the Interleukin-12/STAT4 Axis in Breast Cancer by a Bioinformatics Approach.
Núñez-Marrero, Á. R. (2019) · International Journal of Sciences: Basic and Applied Research · Cited by 24
Metadata
- Authors
- Lasek, W., Zagożdżon, R., & Jakobisiak, M.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Lasek, Witold
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2014-02-11
- Volume
- 63
- Issue
- 5
- Pages
- 419-435
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC3994286
- OpenAlex
- W2025459290
- Cited by
- 495
- References
- 354
- Citations by year
- 2026: 23 · 2025: 40 · 2024: 42 · 2023: 49 · 2022: 52 · 2021: 53 · 2020: 64 · 2019: 41 · 2018: 33 · 2017: 32 · 2016: 33 · 2015: 21 · 2014: 7
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (316254)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- IL-12, cancer immunotherapy, cancer vaccines, gene therapy, immunocytokines, natural killer cells, cytotoxic T lymphocytes, antitumor immunity
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Genetic Therapy, Interleukin-12, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.